Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 11;32(4):226.
doi: 10.3390/curroncol32040226.

Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature

Affiliations
Review

Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature

Giulia Trovarelli et al. Curr Oncol. .

Abstract

Bone metastases are a major concern in cancer management since they significantly contribute to morbidity and mortality. Metastatic lesions, commonly arising from breast, prostate, lung, and kidney cancers, affect approximately 25% of cancer patients, leading to severe complications such as pain, fractures, and neurological deficits. This narrative review explores contemporary approaches to bone metastases, emphasizing a multidisciplinary strategy and the evolving concept of oligometastatic disease. Oligometastases, defined by limited metastatic spread (1-5 lesions), offer a potential window for curative treatment through aggressive interventions, including stereotactic ablative radiotherapy and resection surgery. Tumor boards, integrating systemic therapies with local interventions, are crucial to optimize treatment. Despite promising results, gaps remain in defining optimal treatment sequences and refining patient selection criteria. Future research should focus on personalized approaches, leveraging biomarkers and advanced imaging to enhance outcomes and the quality of life in patients with bone metastases.

Keywords: bone metastases; multidisciplinary approach; oligometastases; palliative care; quality of life; surgical treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Dillekås H., Rogers M.S., Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8:5574–5576. doi: 10.1002/cam4.2474. - DOI - PMC - PubMed
    1. Hage W.D., Aboulafia A.J., Aboulafia D.M. Incidence, Location, and Diagnostic Evaluation of Metastatic Bone Disease. Orthop. Clin. N. Am. 2000;31:515–528. doi: 10.1016/S0030-5898(05)70171-1. - DOI - PubMed
    1. Riccio A.I., Wodajo F.M., Malawer M. Metastatic carcinoma of the long bones. Am. Fam. Physician. 2007;76:1489–1494. - PubMed
    1. Jiang W., Rixiati Y., Zhao B., Li Y., Tang C., Liu J. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J. Orthop. Surg. 2020;28:2309499020915989. doi: 10.1177/2309499020915989. - DOI - PubMed

LinkOut - more resources